<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04588129</url>
  </required_header>
  <id_info>
    <org_study_id>LB-102-002</org_study_id>
    <nct_id>NCT04588129</nct_id>
  </id_info>
  <brief_title>Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers</brief_title>
  <official_title>An Open Label Positron Emission Tomography (PET) Study to Evaluate Dopamine Receptor Occupancy of LB-102 Administered Orally to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LB Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>LB Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label study in 4 cohort of 4 healthy volunteers each designed to evaluate the&#xD;
      dopamine receptor occupancy of LB-102 at various doses and timepoints.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, open label study designed to evaluate the dopamine receptor occupancy in&#xD;
      healthy subjects. There will be 4 cohorts consisting of 4 subjects each. Eligible subjects&#xD;
      will receive 1 or 2 doses of LB-102 on Day 1: subjects in the final cohort will be dosed for&#xD;
      5 days BID (ie twice/day) on an inpatient basis. This will be an open label study. Blood&#xD;
      samples for pharmacokinetic (PK) and safety assessments will be collected at screening,&#xD;
      immediately pre-dose, and during/before/after PET scan. Subjects enrolled in the inpatient&#xD;
      cohort will be monitored daily. Follow-up after discharge will consist of a phone call the&#xD;
      evening of discharge and the next day to check on subjects. This will be an adaptive study&#xD;
      and doses in cohorts 2-4 will be determined after PET data from Cohort 1 are obtained.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 5, 2021</start_date>
  <completion_date type="Anticipated">November 15, 2021</completion_date>
  <primary_completion_date type="Actual">September 17, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain Receptor Occupancy as Measured by Positron Emission Tomography</measure>
    <time_frame>2.5 hours post LB-102 dose</time_frame>
    <description>PET scan of D2/D3 receptor occupancy using raclopride as a tracer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain Receptor Occupancy as Measured by Positron Emission Tomography</measure>
    <time_frame>7.5 hours post LB-102 dose</time_frame>
    <description>PET scan of D2/D3 receptor occupancy using raclopride as a tracer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain Receptor Occupancy as Measured by Positron Emission Tomography</measure>
    <time_frame>23.5 hours post LB-102 dose</time_frame>
    <description>PET scan of D2/D3 receptor occupancy using raclopride as a tracer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as Measured by Reported Adverse Events</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Measurement of clinical events as determined by medical staff reporting</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>LB-102 50 mg, single dose Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LB-102 formulated capsule will be administered orally once daily for one day in up to 4 subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LB-102 xx mg, single dose Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LB-102 formulated capsule will be administered orally once daily for one day in up to 4 subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LB-102 xx mg, single dose Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LB-102 formulated capsule will be administered orally once daily for one day in up to 4 subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LB-102 xx mg, multiple dose Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LB-102 formulated capsule will be administered orally twice daily for one day in up to 4 subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LB-102</intervention_name>
    <description>(N-Methyl amisulpride)</description>
    <arm_group_label>LB-102 50 mg, single dose Cohort 1</arm_group_label>
    <arm_group_label>LB-102 xx mg, multiple dose Cohort 4</arm_group_label>
    <arm_group_label>LB-102 xx mg, single dose Cohort 2</arm_group_label>
    <arm_group_label>LB-102 xx mg, single dose Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Body Mass Index (BMI) ≥ 18 and ≤ 30 kg/m2 at screening visit. Competent to provide informed&#xD;
        consent.&#xD;
&#xD;
        Subjects must be in good general health as determined by medical history and physical&#xD;
        examination with no clinically significant medical findings and no history of significant&#xD;
        medical disease (e.g., cardiovascular, pulmonary, renal, etc.) or acute condition with the&#xD;
        past 30 days, as determined by the study investigators.&#xD;
&#xD;
        Have normal clinical laboratory test results and ECG, which are not considered to be&#xD;
        clinically significant by the Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Are pregnant or lactating.&#xD;
&#xD;
          2. Have a history or presence of significant cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrine, neurological or psychological/psychiatric disorders&#xD;
             which, in the opinion of the Investigator, increases the risk of the study drug or may&#xD;
             confound the interpretation of study measures.&#xD;
&#xD;
          3. Clinically significant abnormal findings on physical examination or vital signs as&#xD;
             determined by Investigator.&#xD;
&#xD;
          4. Individuals with pacemakers, aneurysm clips, shrapnel, or other restricted implanted&#xD;
             metallic devices will be excluded from study. All subjects complete the standard MRI&#xD;
             screening questionnaire prior to MRI.&#xD;
&#xD;
          5. History or presence of psychiatric or neurological disease or condition, as determined&#xD;
             by the Investigator.&#xD;
&#xD;
          6. History of seizures.&#xD;
&#xD;
          7. Subject with any history or current evidence of suicidal behavior.&#xD;
&#xD;
          8. Unwilling to complete any planned study assessments.&#xD;
&#xD;
          9. Have a history of blood donation in excess of 500 mL of blood within 30 days prior to&#xD;
             Screening.&#xD;
&#xD;
         10. Have received treatment with an investigational drug or device within 30 days prior to&#xD;
             Screening.&#xD;
&#xD;
         11. Have a positive test for Human Immunodeficiency Virus (HIV) antibodies 1 and 2,&#xD;
             Hepatitis B Surface Antigen (HBsAg) or Hepatitis C Virus (HCV) antibody.&#xD;
&#xD;
         12. Any subject who is known to be allergic to the study drug or any components of the&#xD;
             study drug.&#xD;
&#xD;
         13. The subject has a fasting blood glucose ≥ 126 mg/dL or hemoglobin A1c (HbA1c) ≥ 6.5%&#xD;
             at Screening.&#xD;
&#xD;
         14. The subject has a history of QT prolongation or dysrhythmia or a family history of&#xD;
             prolonged QT interval or sudden death.&#xD;
&#xD;
         15. Clinically significant abnormal finding on ECG (electrocardiogram) and/or evidence of&#xD;
             any of the following cardiac conduction abnormalities at Screening:&#xD;
&#xD;
               1. Heart rate &lt; 40 bpm and &gt; 100 bpm (based on the ECG reading)&#xD;
&#xD;
               2. QTcF interval &gt; 450 msec for males and females&#xD;
&#xD;
               3. PR interval ≥ 200 msec&#xD;
&#xD;
               4. Intraventricular conduction delay with QRS duration &gt; 120 msec&#xD;
&#xD;
               5. Evidence of second- or third-degree atrioventricular block (AVB)&#xD;
&#xD;
               6. Electrocardiographic evidence of complete left bundle branch block (LBBB),&#xD;
                  complete right bundle branch block (RBBB), or incomplete LBBB&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dean Wong, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.LBPharma.us</url>
    <description>Corporate Website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

